Literature DB >> 3794935

Lactulose-rhamnose intestinal permeability in children with cystic fibrosis.

J Leclercq-Foucart, P P Forget, J L Van Cutsem.   

Abstract

The lactulose-rhamnose intestinal permeability test was performed in 10 cystic fibrosis (CF) children. Urine was collected for 5 h after oral intake of the test solution. A single thin-layer chromatography followed by densitometry was used for the measurement of lactulose and rhamnose concentrations in the urine specimens. The excretion of each molecule was expressed as the percentage of the orally administered dose excreted and the lactulose-rhamnose ratio was the ratio of the percentage quantities of each probe molecule excreted. The mean lactulose-rhamnose excretion ratio in CF patients and controls was 0.16 and 0.038, respectively (p less than 0.001). The mean 5-h lactulose excretion was 2% and 0.28% in CF patients and control subjects, respectively (p less than 0.001). The mean 5-h rhamnose excretion was 12.8% and 7.6% in CF patients and control subjects (p less than 0.05). We conclude that CF patients have an increased intestinal permeability to lactulose and rhamnose. Further studies are needed in order to elucidate the mechanisms involved as well as the eventual nutritional implications.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3794935     DOI: 10.1097/00005176-198701000-00012

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  13 in total

Review 1.  Cystic fibrosis, pathophysiological and clinical aspects.

Authors:  H J Neijens; M Sinaasappel; R de Groot; J C de Jongste; S E Overbeek
Journal:  Eur J Pediatr       Date:  1990-08       Impact factor: 3.183

2.  Cows' milk sensitive enteropathy in cystic fibrosis.

Authors:  S M Hill; A D Phillips; M Mearns; J A Walker-Smith
Journal:  Arch Dis Child       Date:  1989-09       Impact factor: 3.791

Review 3.  Small-intestinal abnormalities in cystic fibrosis patients.

Authors:  E Eggermont; K De Boeck
Journal:  Eur J Pediatr       Date:  1991-10       Impact factor: 3.183

4.  Intestinal permeability in Crohn's disease.

Authors:  M S Murphy; E J Eastham; R Nelson; A D Pearson; M F Laker
Journal:  Arch Dis Child       Date:  1989-03       Impact factor: 3.791

5.  Small intestinal permeability and orocaecal transit time in cystic fibrosis.

Authors:  A M Dalzell; N S Freestone; D Billington; D P Heaf
Journal:  Arch Dis Child       Date:  1990-06       Impact factor: 3.791

6.  Urinary mannitol: lactulose excretion ratios and jejunal mucosal structure.

Authors:  K A Nathavitharana; D R Lloyd; F Raafat; G A Brown; A S McNeish
Journal:  Arch Dis Child       Date:  1988-09       Impact factor: 3.791

7.  Vindaloo and you.

Authors:  I Bjarnason; S Levi; P Smethurst; I S Menzies; A J Levi
Journal:  BMJ       Date:  1988 Dec 24-31

Review 8.  Crohn's disease and cystic fibrosis.

Authors:  J D Lloyd-Still
Journal:  Dig Dis Sci       Date:  1994-04       Impact factor: 3.199

9.  Increased levels of anti-glycan antibodies in patients with cystic fibrosis.

Authors:  T O Hirche; J Stein; H Hirche; J Hausmann; T O Wagner; F Behrens; Oliver Schröder
Journal:  Eur J Med Res       Date:  2011-09-12       Impact factor: 2.175

10.  Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis.

Authors:  Thomas Flass; Suhong Tong; Daniel N Frank; Brandie D Wagner; Charles E Robertson; Cassandra Vogel Kotter; Ronald J Sokol; Edith Zemanick; Frank Accurso; Edward J Hoffenberg; Michael R Narkewicz
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.